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ABSTRACT – Background and Objectives: Lack of insight is a cardinal feature of psycho -
sis. Insight has been found to be a multidimensional concept, including awareness of hav-
ing a mental illness, ability to relabel psychotic phenomena as abnormal and compliance
with treatment., which can be measured with the Schedule for Assessment of Insight
(SAI-E). The aim of this study was to validate the Spanish version of SAI-E.
Methods: The SAI-E was translated into Spanish and back-translated into English, which
was deemed appropriate by the original scale author. Next, the Spanish version of the SAI-E
was administered to 39 patients with schizophrenia or schizoaffective disorder (DSM-IV cri-
teria) from a North Peruvian psychiatric hospital. The Positive and Negative Syndrome Scale
for Schizophrenia (PANSS) and the Scale of Unawareness of Mental Disorder (SUMD) were
also administered. Specifically, internal consistency and convergent validity were assessed.
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Introduction
Lack of insight has been considered a cardi-
nal feature of psychotic disorders, particularly
schizophrenia1. Lack of insight in psychosis is
also associated with greater psychopatholog-
ical severity, poorer psychosocial functioning,
longer duration of untreated psychosis2,3,
poorer compliance, increased readmissions,
especially compulsorily4, and overall, with a
poorer prognosis4,6.Over the last 20 years, a
multidimensional model of insight has been
consistently replicated7-9. In particular, in
1990 David proposed three different, albeit
related, dimensions: awareness of having a
mental illness, treatment compliance, and the
ability to characterize previous psychotic
symptoms as pathological. Amador (1993) dis -
tinguished awareness from attribution10,11
and emphasized awareness of the social con-
sequences of the illness6.
However, the mechanisms underlying lack
of insight in psychosis remain unknown, al-
though psychological12, psychopathologi-
cal13 and neuropsychological14 theories have
been proposed, including the role of cultural
factors15,16.
With regard to neurocognitive deficits,
both general cognition and executive function
impairments have been linked to poor in-
sight in schizophrenia14. Of note, these cog-
nitive deficits appear to precede the onset of
psychosis17.
From a psychodynamic perspective, lack
of insight has been considered to be a denial
mechanism which might protect patient self-
esteem18. This may be supported by the known
association between insight and severity of
depressive symptoms19, although the role of
insight in suicidal risk remains unclear20. Both
negative and positive symptoms severity has
been associated with impaired insight. How-
ever, depressive symptoms were found to have
a positive relationship with insight22,23.
Hence, insight assessment seems to have
crucial implications on patient management.
Thus, several scales have been validated
for the multidimensional assessment of in-
sight: the Insight and Treatment Attitudes
Questionnaire (ITAQ)11, the Schedule for the
Assessment of Insight (SAI)9 and extended
version (SAI-E)24, the Scale to Assess Un-
awareness of Mental Disorder (SUMD)10,
and the Birchwood Self-report Insight Scale
(IS)25. These scales showed high levels of
correlation, hence insight can be measured in
spite of its conceptual complexity26.
Results: Internal consistency between the 11 items of the SAI-E was found to be good to
excellent (α = 0.942). Compliance items did not contribute to internal consistency (A = 0.417,
B = 572). Inter-rater reliability was excellent (ICC = 0.99). Regarding concurrent validity, the
SAI-E total score correlated negatively with the lack of insight and judgement item of the
PANNS (r = -0.91, p < 0.01) and positively with the SUMD total score (r = 0.92, p < 0.001).
Conclusions: The Spanish version of the SAI-E scale was demonstrated to have both
excellent reliability and external validity in our sample of South American Spanish-speak-
ing patients with schizophrenia spectrum disorders.
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The expanded version of SAI9, the SAI-E24
is a semi-structured interview used to measure
three insight dimensions in accordance with
David’s model9. This scale has been validated
in several languages, including Greek4, Por-
tuguese27 and Arabic28, Tamil29 and Man-
darin (ref) (among others)4,27-29. Although no
SAI-E Spanish version has been validated to
date, the Scale of Unawareness of Mental
Disorder (SUMD)10 had been validated in
Spanish30, thus it was available to use as a val-
idating criterion in this study.
The aim of this study was to evaluate the
reliability and validity of a Spanish version of
the SAI-E.
Methods
Sample
The sample for this study comes from the
“Centro de Reposo de Enfermedades Men-
tales de Piura y Talara” (CREMPT), placed in
‘San Juan de Dios’ Hospital (Piura, Peru). In
this region, the mother tongue of the vast
majority of the population is Spanish. How-
ever, given the high levels of social depriva-
tion in this area, outpatient status does not
necessarily mean clinical stability. Thus, both
in- and outpatients were approached over the
period from October 2013 to January 2014.
Those patients with schizophrenia or
schizoaffective disorder according to the
‘Structured Clinical Interview for DSM-IV’31
were invited to participate in the study. A
history of brain injury and drugs abuse were
exclusion criteria. Participants provided writ-
ten informed consent.
The study obtained ethical approval from
the local Ethics Committee and all partici-
pants signed informed consent.
Assessments and scales
Sociodemographic and clinical variables
were recorded. In particular, age, gender and
level of education were considered for the
analyses. Also, general psychopathology was
assessed with the Positive and Negative Syn-
drome Scale (PANSS)32, which also includes an
item for the assessment of (lack of) insight and
judgement, i.e. the higher the score, the poorer
the insight. Also, both the SAI-E and SUMD
were used for this validation study purposes.
The Schedule for Assessment of Insight –
Expanded version (SAI-E) was used to eval-
uate insight. This is a semi-structured inter-
view easily applicable to clinical practice
that provides separate insight scores based on
David’s model9: ‘awareness of mental ill-
ness’, ‘relabeling of psychotic symptoms as
abnormal’ and ‘compliance’.
The Scale of Unawareness of Mental Dis-
order (SUMD) measures those insight di-
mensions proposed by Amador10,33. Specifi-
cally, three general items evaluate awareness
of having a mental illness, awareness of treat-
ment effects, and awareness of social conse-
quences of mental illness. In addition, 17
items assess awareness and attribution of spe-
cific symptoms33. The Spanish version of the
SUMD30 was taken as the “gold standard” for
this validation study.
The Global Assessment of Functioning
(GAF)34 was used to measure overall psy-
chosocial functioning, which ranges from 0
(poor functioning) to 100 (no functioning
impairment at all).
Procedures
All the above assessments were carried
out by the same senior psychiatrist (JS). Also,
a second rater (AR), who was blind to the
SAI-E scores, administered the SAI-E to a
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subsample formed of 10 patients randomly
selected and scored separately by JS, in order
to test the inter-rater reliability. The evalua-
tion was conducted separately, with a maxi-
mum difference of two days.
Statistical analysis
The statistical analyses were performed
using SPSS 20.0 (Chicago, Il, USA). First,
the internal consistency of the Spanish SAI-
E version was calculated using Cronbach’s
alpha coefficient. Second, intraclass correla-
tion coefficients (ICC) were estimated in or-
der to measure the inter-rater reliability, while
the external validity was measured with the
SUMD and PANSS insight item through bi-
variate correlations. Also, further bivariate
correlations between five psychopathological
dimensions from a PANNS32 factorial analy-
sis35 and the three insight dimensions as-
sessed by the SAI-E were conducted.
Results
Sample characteristics
The sample was composed of 39 patients.
The sociodemographic and clinical charac-
teristics of the sample are shown in Table 1.
Of relevance, most of patients were seve rely
psychotic. Thus, the mean score of PANSS to-
tal score was 80.46 (± 19.17), including very
limited overall insight (PANSS lack of insight
item: 4.46 ± 1.60). The mean total score for
the SAI-E was 13.28 ± 8.68 and SUMD to-
tal score mean was 9.82 ± 3.93. These scales
ratings are presented in Table 2.
Internal validity SAI-E
For evaluating internal validity, Cronbach’s
alpha coefficient was estimated. In particular,
for total insight this coefficient was 0.942.
Coefficients for individual items are detailed
in Table 3.
Inter-rater reliability
The inter-rater reliability was calculated
using the ICC in a subsample of (n = 10) pa-
tients, which ranged from 0.992 to 1. The
ICC for the total subscale was 0.99. ICC was
used instead of the Kappa index due to the
quantitative and continuous nature of the
variables, with the risk of accepting that our
sample is normally distributed.
External validity
In terms of external validity, the insight item
of the PANSS and the SUMD scores showed
similar significant bivariate correlations with
the three insight dimensions proposed by
David, which are presented in Table 4.
Insight dimensions correlations
with psychopathological
symptoms
Table 5 shows the correlations between the
three dimensions of insight and five PANSS
dimensions. Awareness of illness correlated
with the Positive factor and Excited factor
(r = -0.521, r = -0.358, respectively, p < 0.01).
Relabeling of symptoms was found to corre-
late with both the Positive (r = -0.617, p < 0.01)
and Disorganized factor; (r = -0.365, p < 0.05).
Need for treatment showed significant corre-
lations with Positive (r= -0.522, p < 0.01),
Disorganized (r = -0.360, p < 0.05) and Ex-
cited factors; (r = -0.332, p < 0.05).
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Table 1
Sociodemographic and clinical variables (n = 39)
n (%)
Gender Males 25 (64.1)
Females 14 (34.9)
Ethnicity Mestizo 36 (92.3%)
Caucasian 1 (2.6%)
Asian 1 (2.6%)
Afro-american 1 (2.6%)
Employment Status Unemployed 26 (66.7%)
Active 9 (23.1%)
Retired 1(2.5%)
Student 3 (7.7%)
Marital Status Single 35 (89.7%)
Married 4 (10.3%)
Residential area Urban 23 (59%)
Rural 16 (41%)
Education level None 1(2.5%)
Primary school 12 (30.8%)
Secondary school 16 (41%)
University 5 (12.8%)
Technical college 5 (12.8%)
Diagnosis Schizophrenia 35 (89.7%)
Schizoaffective Disorder 4 (10.3%)
Family history Unknown 4 (10.3%)
Affective 5 (12.8%)
Psychosis 9 (23.1%)
None 21 (53.8%)
Clinical status First episode 4 (10.3%)
Acute relapse 14 (35.9%)
Clinically stable 21 (53.8%)
Means (S.D.)
Age (years) 38 (12.99)
Age at illness onset (years) 23 (7.07)
Duration of illness (months) 181 (151.67)
Number of admissions 2.56 (2.68)
PANSSa total score 80.46 (19.17)
Positive symptoms 18.41 (7.70)
Negative symptoms 23.54 (7.48)
General Psychopathology 38.54 (10.16)
GAFb 55.64 (20.52)
aPANNS: Positive and Negative Syndrome Scale. bGAF: Global Assesment of Functioning Scale (DSM-IV-TR).
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Table 2
Mean scores and S.D. of SAI-E items, SUMD total
score and G12 of PANSS
Item Mean S.D.
SAI 1 1.18 0.885
SAI 2 0.95 0.857
SAI 3 0.82 0.854
SAI 4 0.62 0.711
SAI 5 0.77 0.81
SAI 6 1.15 0.779
SAI 7 1.87 1.321
SAI 8 1.64 1.367
SAI 9 1.97 1.478
SAI SUB 11 7.954
SAI A 1.71 0.515
SAI B 0.66 0.815
SAI C 5.03 1.345
SAI TOTAL 13.28 8.678
G12 4.46 1.603
SUMD TOTAL 9.82 3.933
Table 3
Internal validity of the SAI-E Spanish version
SAI-E Items Cronbach’s alpha
SAI 1 0.778
SAI 2 0.813
SAI 3 0.826
SAI 4 0.752
SAI 5 0.733
SAI 6 0.864
SAI 7 0.848
SAI 8 0.904
SAI 9 0.905
SAI A 0.417
SAI B 0.572
Discussion
Main findings
This study aimed to validate the Spanish
version of the SAI-E when administered to a
sample of Spanish-speaking patients with
schizophrenia and related disorders. In partic-
ular, our results appear to validate the use of
this Spanish version of the SAI-E to assess in-
sight in patients with psychosis in Latin Amer-
ican in- and outpatient settings given its good
internal and external validity and reliability.
Specifically, the mean total score of SAI-
E from our study (13.28) was similar to pre-
vious samples of inpatients27,36, which are
comparable with our mixed setting in terms
of symptoms severity given the specific so-
cioeconomic characteristics of North-Peru,
particularly the limited access to inpatient
care (the threshold for admissions is much
higher than in the Western world). Thus, par-
ticipants in previous outpatient studies were
reported to have similar levels of total insight
to our subsample of outpatients4,28 (mean
SAI-E: 16.48).
With regard to the inter-rater reliability
(n = 10), our ICC was 0.99 for the total in-
sight score. Also, individual items ICCs
ranged from 0.992 to 1, which is in line with
recent validation studies in Greece4, Brazil27
and Tunisia28; being all above scores over
0.72, which had been found in the validation
study of the original version of the SAI5.
Thus, the Spanish version of the SAI-E
showed satisfactory internal consistency with
a Cronbach’s alpha of 0.94 for the total scale
scores. Of note, those items concerning ad-
herence were found to be relatively low (0.417
and 0.572 respectively). However, these find-
ings were in line Konstantakopoulus study et
al.’s4, while the Nakhli validation study found
a higher consistency across items28. These dif-
ferences may be due to the characteristics of
samples. Thus, these two studies4,28 used a
sample of chronic patients and outpatients re-
spectively, whereas the study by Nakhli and
colleagues28 was limited to stable patients
(PANNS total < 90 and a minimum duration
of the illness of three years).
Alternatively, these mixed findings may
be also be related to the existence of differ-
ent adherence profiles. Thus, Roe et al.37 de-
scribed four narrative profiles of insight (in-
tegrative insight, accepts illness / rejects
labels, passive insight, and rejects illness)
indicating the importance of distinguishing
adherence from insight [38]. Thus, Konstan-
takopoulus et al4 described two groups of
patients in relation to this aspect of insight,
namely “insight induced” and “insight spon-
taneous”, which are similar to the passive
and integrative profiles reported by Roe et al,
respectively. Adherence may also be affected
by other external contributing factors such as
past experiences of treatment, therapeutic re-
lationships with the mental health profes-
sional, the level of community support and
cultural background24.
Of relevance, convergent validity was found
to be satisfactory for total scores and indi-
vidual items when compared with the PANSS
insight item, which is in full agreement with
previous studies4,28,36. In addition, a good
correlation between the total score of the
SAI-E and SUMD was reached. Moreover,
when individual insight dimensions were an-
alyzed, these correlations remained signifi-
cant for most SAI-E and SUMD items, con-
sistently with a previous study39.
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Table 4
Dimensional correlation between SAI-E, SUMD items and G12 of PANNS
Items Attribution Awareness SUMD
SAI-E dimensons SUMD1 SUMD SUMD SUMD2 TOTAL G12
Awareness of illness -0.940** -0.867**
Relabelling of symptoms -0.732** -0.732** -0.857**
Need for treatment -0.630** -0.819**
SAI-E Total -0.923** -0.907**
Spearman’s coefficient. ** Significant at the 0.01 level (bilateral) Correlation.
Table 5
Dimensional correlations between SAI-E and PANNS
PANNS dimensions
SAI-E dimensions
Positive Negative Disorganized/concrete Excited Depressed
Factor Factor Factor Factor Factor
Awareness of illness -0.521** 0.258 -0.287 -0.358* 0.035
Relabelling of Symptoms -0.617** 0.123 -0.365* -0.304 -0.007
Need for treatment -0.522** -0.009 -0.360* -0.368* -0.054
SAI TOTAL -0.602** 0.127 -0.386* -0.359* 0.013
Spearman’s coefficient: *Correlation significant at the 0.05 level (bilateral). **Significant at the 0.01 level (bi-
lateral) Correlation.
Associations of insight dimensions
with psychopathology and
functioning
Of note, with regard to psychopatholgy and
insight, we replicated a negative relationship
between the PANSS positive factor and the
three insight dimensions. Thus, our results
are in full agreement with a previous meta-
analysis22, which encompasses 40 studies
and revealed a small negative association be-
tween awareness of mental illness and posi-
tive and general symptoms. Also, both the
disorganized and excited factors showed sig-
nificant negative correlations with insight.
However, our study failed to replicate asso-
ciations of depressive and negative symp-
toms with insight dimensions, in line with a
previous study40. These findings were, how-
ever, relatively in contrast to the aforemen-
tioned meta-analysis22, which may have been
due to the overall psychotic severity of our
patients. In keeping with our results, Cuesta
et al. also found a correlation with disorga-
nized, excited and negative schizophrenic di-
mensions while they failed to report further
relationships with other Positive and Nega-
tive Syndrome Scale dimensions such as de-
pression and positive symptoms41.
Insight had also been reported to predict
long-term functioning in psychosis6. Thus,
we found a cross-sectional association be-
tween total insight and psychosocial func-
tioning, consistently with previous studies4,42.
It could therefore be speculated that insight
may improve long-term psychosocial func-
tioning in patients with psychotic disorders
via increased compliance with medication,
which contributes to long-term symptomatic
stability. In addition, engagement with men-
tal health services, which has been associated
with insight6, may help patients meet com-
plex social needs such as employment and
housing. Hence, insight may positive affect
thus overall psychosocial functioning, par-
ticularly taking into account the high levels of
social deprivation in our catchment area.
Influence of culture
Of relevance, in the study population re-
gion, which is close to the Andean highlands,
certain ‘cultural syndromes’ have been pre-
viously described, particularly the so-called
“Susto” (shock in Spanish), which is highly
prevalent in Peruvian Andes43. This phe-
nomenon consists of a magical or spiritual
explanation for all kinds of ailments, which
originally comes from Quechua culture, in-
cluding a wide range of variations throughout
Latin America. The soul (not according to the
Christian meaning) is thought to leave the
body due to strong reactions in places in-
habited by mythical beings. Thus, symptoms
can range from mild somatic symptoms such
as headaches to hallucinations and delusions.
More severe patients can go on to die by sui-
cide in relation to nihilistic delusions or as
coping strategies with medically unexplained
symptoms44. Also, those affected by this
‘syndrome’ receive treatments and rituals de-
livered by shamans and healers. In our study,
65.5 % of participants reported having ‘ever’
been seen by local healers or shamans. This
alternative approach to mental illness con-
ceptualisation relates to previously reported
non-medical models of illness45,46. Of note,
our results appear to support the usefulness of
the SAI- E to measure insight across cul-
tures15,29. Thus, since the SAI-E consists of a
‘semi-structured’ interview enquiring about
insight dimensions, the examiner can formu-
late the SAI-E questions in accordance with
the patient cultural background.
Strengths and limitations
To our best knowledge, this is the first study
aimed to validate the Spanish version of the
SAI-E and can be generalized to other Spanish-
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speaking countries. Thus, while our findings
may contribute to this area, namely insight in
psychosis, replication studies are needed and
our findings should be taken cautiously.
In addition, several study limitations should
be borne in mind when interpreting our re-
sults. In particular, our sample may have been
too small, which was also mixed with regard
to patient status (both in- and outpatients
were included) and illness stage, but the most
important limitation is the small sample for in-
ter-rater reliability. Also, the same researcher
(JS), who had a good knowledge of the patient
clinical status and cultural background, ad-
ministered the SAI-E, the PANSS, and SUMD
in the same interview, which may have biased
these ratings and increased their correlation.
Conclusion
In summary, the SAI-E Spanish version has
been demonstrated to have sufficient external
validity and psychometric properties for it to
be used for a multidimensional insight as-
sessment in Spanish-speaking patients in Peru
with schizophrenia and related disorders.
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